How Advertising Disclosure Rules Differ Across Georgia, Arizona, and Tennessee

Georgia and Tennessee wrote a mandatory patient notice into provider advertising in 2026. Arizona passed a similar bill and lost it to a veto. Any honest stem cell advertising disclosure law comparison has to account for all three outcomes, because the third one is a blank space that marketing teams keep filling in with assumptions.

TLDR: Georgia and Tennessee now require a fixed statutory notice in advertising by providers who offer therapies the FDA has not approved, both effective July 1, 2026, and Georgia ties that notice to the largest type used in the ad. Arizona has no advertising disclosure requirement at all, because Governor Katie Hobbs vetoed SB 1214 on June 19, 2026. Utah’s posting rule remains the strictest in the country. Banking adipose tissue is a preservation service, and it does not guarantee eligibility, access, or clinical benefit.

Important Disclaimer: Save My Fat connects patients and providers to a United States tissue bank and does not provide FDA-approved treatments or cures. Adipose tissue and stromal vascular fraction are investigational and are not FDA approved. How these statutes apply to a given practice depends on facts this article cannot evaluate, so Save My Fat does not guarantee eligibility, access, or clinical benefit and publishes this comparison for educational purposes only. Patients should consult their own licensed healthcare professionals, and providers should consult their own counsel.

Three states took up the same question inside a single year. What must a clinic tell the public before advertising a therapy the FDA has not approved? Georgia and Tennessee answered with exact wording. Arizona’s answer never became law.

One campaign running across Chattanooga and north Georgia carries a notice duty in both places, worded differently in each. The same campaign in Phoenix carries none, so state stem cell marketing rules have to be read one state at a time.

What Georgia Requires in a Stem Cell Advertisement

Georgia House Bill 1275 became Act 453, signed May 11, 2026 and effective July 1, 2026. It creates O.C.G.A. 43-34-49 and lets a physician, or a physician assistant or nurse practitioner under lawful designation, perform human stem cell therapy that is not FDA approved within the scope of practice, with patient advisement and a signed consent form. Unlike Florida, Georgia sets no specialty limitation. The Georgia enacted legislation fixes the notice word for word:

> “THIS NOTICE MUST BE PROVIDED TO YOU UNDER GEORGIA LAW. This physician or his or her designee performs one or more human stem cell therapies that have not yet been approved by the FDA. You are encouraged to consult with your primary care provider before undergoing any human stem cell therapy.”

What Tennessee Requires, and Where It Diverges

Tennessee House Bill 2246 became Public Chapter 1016, signed May 19, 2026 and effective July 1, 2026. It adds to Title 63, Chapter 6, Part 2 and defines two categories rather than one, stem cell therapy and regenerative medicine therapy. The Tennessee public chapter requires this notice:

> “THIS NOTICE MUST BE PROVIDED TO YOU UNDER TENNESSEE LAW. This physician performs one (1) or more stem cell or regenerative medicine therapies that have not yet been approved by the United States food and drug administration. You are encouraged to consult with your primary care provider before undergoing any stem cell or regenerative medicine therapy.”

Georgia covers the physician “or his or her designee,” matching its allowance for physician assistants and nurse practitioners. Tennessee names only the physician but adds the second category, so an ad for something marketed as regenerative medicine triggers the notice even when the words stem cell never appear.

Arizona Passed a Bill and Still Has No Rule

Arizona SB 1214, the Arizona Stem Cell and Regenerative Therapy Act, cleared the Senate on March 4, 2026, passed the House on June 9, 2026, and won final Senate passage on June 12, 2026. Governor Katie Hobbs vetoed it on June 19, 2026, and no override followed.

The Arizona bill text would have added A.R.S. 32-3235 and 32-3236, requiring an all-caps advertising disclosure, provider continuing education, a five-element written consent, and 10,000 dollars in statutory damages per violation. None of it is in force, so there is no Arizona notice text to reproduce. That is not the same as no oversight: FDA issued a warning letter to Innate Healthcare Institute of Scottsdale on August 15, 2025.

A Stem Cell Advertising Disclosure Law Comparison, Side by Side

The fastest way to see the divergence is to line the states up on what is required, how it must look, and what limits the scope. Florida and Utah anchor the two ends of the range.

The notice text is the easy part. Two of these states also govern how the notice must look, and one governs the supplier.

The Type Size Rule Marketing Teams Miss

Compliance review usually stops once the required sentence lands in the footer. Georgia and Utah make that insufficient. Georgia requires the notice in type no smaller than the largest type size used in the advertisement, and Utah applies the same rule to advertising, at a font no smaller than the largest used, or clearly spoken in audio.

A billboard with a 200 point headline forces the Georgia notice to 200 point type. An oversized hero headline on a landing page sets the floor for that page.

Utah goes further on the physical posting. Under the Utah statutory text, the notice must appear on paper at least 8.5 by 11 inches, in no less than forty point type, displayed at the entrance and in an area visible to patients. No other state specifies both a paper size and a point size, which is where any utah stem cell disclosure comparison begins.

Florida, Utah, and the Rest of the Map

Florida moved first. CS/CS/SB 1768 became Chapter 2025-185, effective July 1, 2025, and the Florida enrolled bill prescribes its own notice, naming the United States Food and Drug Administration in full. Florida is also the only state here that limits use by clinical category, so anyone weighing florida sb 1768 advertising obligations has to read that limit next to the notice. An ad promising anything outside orthopedics, wound care, or pain management has a problem no notice can fix, as our Florida advertising rules breakdown explains.

Utah Code 58-1-512, amended by S.B. 55 effective May 6, 2026, added something no other state has. A person may supply human cells, tissues, and cellular and tissue-based products to a provider only after receiving written confirmation that the provider will give the notice to each patient. These Utah supplier obligations have no parallel anywhere.

Providers weighing the California disclosure law, in place since 2017, will find the 2026 statutes far more prescriptive, and the multi-state law map tracks stem cell clinic disclosure requirements by state.

Does Any of This Reach Adipose Tissue Banking Ads?

These duties attach to the practitioner performing the therapy, not to a preservation service. Save My Fat does not collect, process, store, or treat, and it does not advertise therapies. Scope still reaches adipose-derived products, though, since none of these laws is limited to birth tissue. The federal layer never switches off either. The FTC’s Health Products Compliance Guidance requires competent and reliable scientific evidence behind express and implied claims, and the FTC enforcement pattern shows that a state notice does nothing about an unsupported claim above it.

Frequently Asked Questions

What disclosure language does each state require in stem cell advertising?

Georgia, Tennessee, Florida, and Utah each prescribe exact wording. Georgia covers a physician or his or her designee. Tennessee covers stem cell and regenerative medicine therapies. Florida and Utah spell out the United States Food and Drug Administration while Georgia writes FDA. Copy each state’s text exactly.

How does Georgia’s advertising rule compare to Florida’s SB 1768?

Both require fixed wording and diverge on two points. Georgia requires the notice in type no smaller than the largest used in the advertisement, a rule Florida’s text does not carry. Florida limits use to orthopedics, wound care, or pain management, while Georgia sets no specialty limitation.

What happens if a provider fails to include required disclosures?

These requirements sit inside medical practice and licensing statutes, so enforcement runs through state licensing authorities. The verified record does not set out a penalty schedule, and Arizona’s proposed private right of action carrying 10,000 dollars in statutory damages died with the veto. Ask your own counsel.

Do these rules apply to adipose tissue banking ads or only to therapy ads?

The notice duties attach to practitioners advertising therapies. Adipose tissue banking for potential future use is storage, not treatment. The scope definitions do reach adipose-derived products, so a provider advertising them is covered. Utah is the exception, adding a written confirmation duty for suppliers in 2026.

Which states currently have the strictest disclosure requirements?

Utah, by a clear margin. It is the only state that dictates the physical notice, requiring paper at least 8.5 by 11 inches in no less than forty point type, posted at the entrance and where patients can see it, plus the supplier duty.

Could Arizona adopt an advertising disclosure requirement later?

Nothing in the veto stops a future legislature from taking the subject up again, and the vetoed text is a public record of one version. As of July 2026, though, Arizona requires no advertising notice, and planning around a rule that does not exist is guesswork.

Key Takeaways

Georgia and Tennessee both enacted advertising notices in 2026 with July 1 effective dates, and both prescribe language that has to be reproduced word for word. Arizona passed a broader bill in both chambers and lost it to a veto on June 19, 2026, leaving no advertising disclosure requirement today and no notice text to publish. The detail that trips teams up is format rather than wording.

Georgia ties the notice to the largest type in the advertisement, and Utah goes further with a printed notice on paper at least 8.5 by 11 inches in no less than forty point type. Underneath every state rule, federal advertising standards still govern the claims themselves. Banking adipose tissue is a preservation decision, and it does not create access to any therapy or guarantee any outcome.

Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.

Patients weighing preservation can review current pricing or reach the team through the contact page with questions about the process.

Save My Fat partners with a U.S.-based tissue bank for laboratory processing and storage.

This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about banking, treatment, or research participation.

About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.

Related guide: compliant marketing standards.